Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM-Skin: Combined Azithromycin and Ivermectin MDA
NCT02775617Phase 4Completed
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Jul 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of azithromycin and ivermectin in yaws, scabies and impetigo (2 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoint: Impetigo Prevalence at 12 Months. Started Jul 2016; status: completed.
02
Drugs
azithromycinivermectin
03
Conditions
yawsscabiesimpetigo
Beyond the preview
Go deeper on NCT02775617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02775617.